



## **AgiOS to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023**

December 21, 2022

CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at [www.agios.com](http://www.agios.com). A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

### **About Agios**

Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has multiple investigational therapies in preclinical development and deep scientific expertise in classical hematology. For more information, please visit the company's website at [www.agios.com](http://www.agios.com).

### **Contacts**

#### **Investors:**

Adam Bero, Kendall IR  
[abero@kendallir.com](mailto:abero@kendallir.com)

#### **Media:**

Jessica Rennekamp  
Senior Director, Corporate Communications  
[Jessica.Rennekamp@agios.com](mailto:Jessica.Rennekamp@agios.com)



Source: Agios Pharmaceuticals, Inc.